News

June 25th, 2021

The Verisense IMU (inertial measurement unit) was the first Shimmer sensor validated following the V3 framework championed by the Digital Medicine Society (DiMe)

June 02nd, 2021

Shimmer America president, Geoff Gill outlines to Pharma Voice.com what needs to be done to transform the use of wearables in clinical trials

March 22nd, 2021

Uses the [email protected]™ platform to assess participants’ emotional responses to a wide variety of stimuli in their own home

March 09th, 2021

[email protected]™ assesses participants’ emotional responses to a wide variety of entertainment, advertisements, marketing materials and other stimuli in their own home

March 02nd, 2021

Shimmer’s Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels

February 02nd, 2021

This neuromarketing technology uses galvanic skin response (GSR) and heart rate to measure participants’ emotional responses

January 12th, 2021

These studies, which are funded by the American Heart Association, will use wearable sensors to increase knowledge of the links between brain and heart health

December 16th, 2020

Shimmers Geoff Gill writes a small thought piece to describe some of the barriers to wider adoption of wearables in remote monitoring and a possible way forward

November 17th, 2020

Verisense Wins 2020 Best of Sensors Award - Shimmers Wearable Sensing Platform Developed Specifically for Clinical Trials

November 10th, 2020

Shimmer’s wearable sensor is now recognized as a medical device in Europe, capable of providing continuous, medical-grade measurements of a person’s activity